Center for Scientific Review; Notice of Closed Meetings, 21374 [E9-10529]
Download as PDF
<![CDATA[
21374
Federal Register / Vol. 74, No. 87 / Thursday, May 7, 2009 / Notices
LTR as a treatment for various cancers,
including human breast, liver, prostate,
and myeloid cancers and fibrosarcomas.
The inventors have shown that the
ERV–9 LTR sense and antisense oligos
can inhibit cancer cell proliferation in
vitro more efficiently than the antisense
oligos of Bcl-2 (G3139) and telomerase
(GRN163), both of which are currently
in cancer clinical trials. The oligos have
minimal effects on the proliferation of
primary normal human cells in vitro.
These oligos have potential as a new
therapeutic agent to suppress tumor cell
growth, either when used alone or in
conjunction with other antisense oligos
or with chemotherapeutic agents such
as VePesid. Furthermore, sense and
antisense RNA transcripts of ERV–9
LTR were detected in many human
normal and tumor cells in this
invention. The sense and antisense RNA
may form double stranded RNA and act
as siRNA to regulate gene expression.
Applications
• Therapeutic oligos of the invention
can be used to treat variety of cancers
including, but not limited to, breast,
liver, myeloid and prostate cancers and
fibrosarcomas.
• The oligos can be used either singly
or as adjuvant therapy with
chemotherapeutic agents.
• ERV–9 LTR related cancers can be
diagnosed by comparative analysis of
the levels of ERV–9 LTR RNAs in
tumors versus those of healthy tissues.
Advantages
• Greater inhibition of cell
proliferation by oligos of the invention
compared to the Bcl-2, telomerase and
MDM2-specific antisense oligos which
are currently in development as cancer
therapies.
• The therapeutic effect of the oligos
is specific for cancer cells as the oligos
do not significantly alter proliferation of
normal human cells.
Development Status: In vivo testing of
therapeutic sense and antisense oligos
in mouse xenograft models has been
successfully conducted.
Market: Cancer is the second leading
cause of death in the United States.
More than 1 million Americans are
diagnosed with cancer each year.
Inventors: Lai Xu (FDA/CDER), Abdel
Elkahloun (NHGRI), Fabio Candotti
(NHGRI), Amy Rosenberg. (FDA/CDER)
Publications: None related to
invention have been published.
Patent Status: U.S. Provisional
Application No. 61/191,911 filed 11 Sep
2008 (HHS Reference No. E–092–2008/
0–US–01).
Licensing Status: Available for
licensing.
VerDate Nov<24>2008
17:03 May 06, 2009
Jkt 217001
Licensing Contact: Surekha Vathyam,
PhD; 301–435–4076;
vathyams@mail.nih.gov.
Dated: April 30, 2009.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E9–10549 Filed 5–6–09; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Cancer
Pathobiology ARRA CR.
Date: May 19, 2009.
Time: 2 p.m. to 6 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hilton Alexandria Old Town, 1767
King Street, Alexandria, VA 22314.
Contact Person: Elaine Sierra-Rivera, PhD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6184,
MSC 7804, Bethesda, MD 20892. 301–435–
1779. riverase@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: Biological Chemistry
and Macromolecular Biophysics; Integrated
Review Group, Biochemistry and Biophysics
of Membranes Study Section.
Date: May 28–29, 2009.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: The Dupont Hotel, 1500 New
Hampshire Avenue, NW., Washington, DC
20036.
Contact Person: Nuria E. Assa-Munt, PhD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4164,
PO 00000
Frm 00064
Fmt 4703
Sfmt 4703
MSC 7806, Bethesda, MD 20892, (301) 451–
1323, assamunu@csr.nih.gov.
Name of Committee: Biological Chemistry
and Macromolecular Biophysics; Integrated
Review Group, Macromolecular Structure
and Function—B Study Section.
Date: May 28–29, 2009.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: The Fairmont Washington, DC, 2401
M Street, NW., Washington, DC 20037.
Contact Person: Arnold Revzin, PhD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4146,
MSC 7824, Bethesda, MD 20892, (301) 435–
1153, revzina@csr.nih.gov.
Name of Committee: Immunology
Integrated Review Group; Cellular and
Molecular Immunology—A Study Section.
Date: May 28–29, 2009.
Time: 8:30 a.m. to 2 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hilton Crystal City, 2399 Jefferson
Davis Highway, Arlington, VA 22202.
Contact Person: Samuel C. Edwards, PhD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4200,
MSC 7812, Bethesda, MD 20892. (301) 435–
1152. edwardss@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel;
Bioengineering Member Conflicts.
Date: May 29, 2009.
Time: 10 a.m. to 11 a.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Ping Fan, MD, PhD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5154,
MSC 7840, Bethesda, MD 20892. 301–435–
1740. fanp@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: April 30, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E9–10529 Filed 5–6–09; 8:45 am]
BILLING CODE 4140–01–M
E:\FR\FM\07MYN1.SGM
07MYN1
]]>Agencies
[Federal Register Volume 74, Number 87 (Thursday, May 7, 2009)]
[Notices]
[Page 21374]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-10529]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Cancer Pathobiology ARRA CR.
Date: May 19, 2009.
Time: 2 p.m. to 6 p.m.
Agenda: To review and evaluate grant applications.
Place: Hilton Alexandria Old Town, 1767 King Street, Alexandria,
VA 22314.
Contact Person: Elaine Sierra-Rivera, PhD, Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6184, MSC 7804, Bethesda, MD
20892. 301-435-1779. riverase@csr.nih.gov.
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
Name of Committee: Biological Chemistry and Macromolecular
Biophysics; Integrated Review Group, Biochemistry and Biophysics of
Membranes Study Section.
Date: May 28-29, 2009.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant applications.
Place: The Dupont Hotel, 1500 New Hampshire Avenue, NW.,
Washington, DC 20036.
Contact Person: Nuria E. Assa-Munt, PhD, Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4164, MSC 7806, Bethesda, MD
20892, (301) 451-1323, assamunu@csr.nih.gov.
Name of Committee: Biological Chemistry and Macromolecular
Biophysics; Integrated Review Group, Macromolecular Structure and
Function--B Study Section.
Date: May 28-29, 2009.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant applications.
Place: The Fairmont Washington, DC, 2401 M Street, NW.,
Washington, DC 20037.
Contact Person: Arnold Revzin, PhD, Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Room 4146, MSC 7824, Bethesda, MD 20892, (301) 435-
1153, revzina@csr.nih.gov.
Name of Committee: Immunology Integrated Review Group; Cellular
and Molecular Immunology--A Study Section.
Date: May 28-29, 2009.
Time: 8:30 a.m. to 2 p.m.
Agenda: To review and evaluate grant applications.
Place: Hilton Crystal City, 2399 Jefferson Davis Highway,
Arlington, VA 22202.
Contact Person: Samuel C. Edwards, PhD, Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4200, MSC 7812, Bethesda, MD
20892. (301) 435-1152. edwardss@csr.nih.gov.
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Bioengineering Member Conflicts.
Date: May 29, 2009.
Time: 10 a.m. to 11 a.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892 (Telephone Conference Call).
Contact Person: Ping Fan, MD, PhD, Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Room 5154, MSC 7840, Bethesda, MD 20892. 301-435-
1740. fanp@csr.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.306,
Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893,
National Institutes of Health, HHS)
Dated: April 30, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. E9-10529 Filed 5-6-09; 8:45 am]
BILLING CODE 4140-01-M
